EQT in advanced talks to acquire Qiagen for over $10bn
Wednesday, October 21, 2026 · first reported by Private Equity Wire
EQT is in advanced talks to buy Qiagen in a deal that would value the molecular testing company at more than $10bn, Bloomberg reported, as relayed by Private Equity Wire. The Swedish manager is said to have made a binding offer above $50 per share. KKR has also put in a bid. Qiagen's board is expected to meet this week to weigh a transaction. Qiagen's US-listed shares rose as much as 9.2% on the report, putting its value near $10.2bn. Talks continue, and no deal is certain.
- Firm
- EQT
- Asset class
- Private equity
- Geography
- Europe
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore on EQT
Everything on this firm →- Centerbridge and Mubadala near £1bn Canaccord Wealth dealPrivate Equity Wire
- Janus acquires $5.7bn in funds as boutique shop winds downCitywire
- SoftBank Was Reported to Be in Early Talks to Acquire Warburg Pincus-Backed Allied UniversalHedgeCo
- KKR inks $2.9bn sale of railcar lessor Infinity Transportation to AresPE Hub +7
- Blackstone and Warburg Pincus explore $10bn IntraFi salePrivate Equity Wire
- Arlington Capital Partners completes take-private of UK photonics firm Gooch & HousegoPE Hub +1